Lung Adenocarcinoma Clinical Trials 2023

What are the top hospitals conducting lung adenocarcinoma research?

When it comes to advancing the understanding and treatment of lung adenocarcinoma, several hospitals are at the forefront of pioneering clinical trials. In Minneapolis, the Masonic Cancer Center at the University of Minnesota is making significant contributions with two active trials focused on this specific type of lung cancer. While their involvement in lung adenocarcinoma research is relatively recent, having recorded their first trial in 2022, they are demonstrating a commitment to pushing boundaries and exploring new avenues for treatment.

Meanwhile, in Boston's esteemed Dana-Farber Cancer Institute, researchers are also actively engaged in two ongoing clinical trials for lung adenocarcinoma. With their first recorded trial dating back to 2020, they have been dedicatedly working towards better outcomes for patients with this form of cancer.

In Houston's renowned MD Anderson Cancer Center at the University of Texas, clinicians and scientists are currently conducting two active clinical trials focusing on lung adenocarcinoma as well. Although they do not yet have any historical records specifically related to these trials on file, their expertise and dedication make them a valuable contributor to the field.

Further expanding our list is Memorial Sloan Kettering Basking Ridge (Consent Only) located in Basking Ridge and Memorial Sloan Kettering Monmouth (Consent Only) situated in Middletown; both facilities have one ongoing trial each for lung adenocarcinoma. While these institutions may have only recently started recording such studies from 2023 onwards depicting that advancements still lie ahead within this particular area but nevertheless signify how medical professionals continuously strive towards improving patient care through innovative investigations.

The collaborative efforts exhibited by these top hospitals demonstrate an unwavering commitment to progressing our knowledge about lung adenocarcinoma and developing more effective treatments for those affected by this condition. Through cutting-edge research conducted across various locations nationwide, we can remain hopeful that a brighter future awaits individuals impacted by this form of lung cancer.

Which are the best cities for lung adenocarcinoma clinical trials?

When it comes to clinical trials for lung adenocarcinoma, several cities are at the forefront of research. Boston, Massachusetts leads with 10 active trials investigating treatments like Phase 1 elzovantinib, PF-07220060, and LXH254. Houston, Texas follows closely behind with 6 ongoing studies focusing on therapies such as Phase 1 elzovantinib and Neoantigen specific TCR-T cell drug product. Fairfax, Virginia is also making strides in this field with 5 active trials exploring interventions like Ceritinib and LP-300. These cities provide valuable opportunities for individuals diagnosed with lung adenocarcinoma to participate in cutting-edge clinical research that may hold promise for improved outcomes and new treatment options.

Which are the top treatments for lung adenocarcinoma being explored in clinical trials?

Exciting advancements are being made in the realm of lung adenocarcinoma treatment, with two cutting-edge options currently under exploration in clinical trials. Leading the pack is LP-300, a promising drug that has initiated one active trial for lung adenocarcinoma since its inception in 2022. Also making waves is the neoantigen specific TCR-T cell drug product, which shows great potential and has sparked interest with one ongoing trial and two all-time trials dedicated to lung adenocarcinoma research. These innovative treatments hold promise for improving outcomes and bringing new hope to patients battling this aggressive form of cancer.

What are the most recent clinical trials for lung adenocarcinoma?

Exciting developments are underway in the realm of clinical trials for lung adenocarcinoma, offering hope and potential breakthroughs for patients. One notable trial involves the NovoTTF-200T System Tumor-Treating Fields (TTFields), a Phase 1 study that explores the efficacy of this innovative treatment approach. Another trial focuses on CISH CRISPR TIL, with both Phase 1 and Phase 2 arms targeting specific cohorts based on PD-L1 expression. Furthermore, an intriguing investigation is examining the use of Oral Restorative Microbiota Therapy (RMT) Capsules to potentially enhance outcomes in affected individuals. Lastly, LP-300 and Neoantigen specific TCR-T cell drug product represent additional avenues being explored to combat lung adenocarcinoma through targeted approaches. These cutting-edge studies hold promise for improved treatments and brighter prospects against this challenging disease.

What lung adenocarcinoma clinical trials were recently completed?

A notable clinical trial investigating Bemcentinib in combination with pembrolizumab for lung adenocarcinoma was successfully completed by BerGenBio ASA in October 2017. This study holds significance as it examined the potential benefits of this therapeutic approach for patients with this specific type of lung cancer. Although further recent trials may exist, information on them is currently unavailable or limited.